期刊
CHEMBIOCHEM
卷 9, 期 9, 页码 1423-1430出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbic.200700625
关键词
alpha-GalCer; alpha-LacCer; cytokines; glycolipids; iNKT cells
资金
- NCI NIH HHS [R21 CA123195, R21 CA123195-02, CA123195] Funding Source: Medline
The invariant natural killer Tcells (iNKT) cells have emerged as an important regulator of immunity to infection, cancer, and autoimmune diseases. They can be activated by glycolipids that bind to CD1d. The most effective iNKT ligand reported to dote is a-galactosylceramide (alpha-GalCer), which stimulates iNKT cells to secrete both Th-1 and Th-2 cytokines. Indiscriminate induction of both types of cytokines could limit the therapeutic potential of iNKT ligands, as Th-1 and Th-2 cytokines play different roles under physiological and pathological conditions. Therefore, a ligand with a biased cytokine-release profile would be highly desirable. Here, we report the synthesis and biological activity of alpha-lactosylceramide (alpha-LacCer). Our data demonstrate that alpha-LacCer con stimulate iNKT cells to proliferate and release cytokines, both in vitro and in vivo. Interestingly, while alpha-LacCer is approximately 1000-times less efficient than alpha-GalCer in inducing Th-7 cytokines, it is as potent as a-GalCer in the induction of Th-2 cytokines; therefore, alpha-LacCer is a novel compound that induces a biased cytokine release. Processing by beta-glycosidase was critical for alpha-LacCer activity. Moreover, in vivo experiments suggest that cc-LacCer is at least as potent as a-GalCer in the treatment of tumors and experimental autoimmune encephalomyelitis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据